Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
US9493549B2 · kind B2 · utility
12Cited by
7References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 13, 2012 |
| Grant date | Nov 15, 2016 |
| Priority date | — |
| Expiry date | Dec 13, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) potent VRC01-like (PVL) antibodies targeted to gp120 having an amino acid substitution in the heavy chain at a residue in the anti-CD4 binding site PVL antibody that is equivalent to Phe43 in CD4 and an amino acid substitution in the light chain, these antibodies having improved potency and breadth.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.